Thymosin beta-4 and its fragment Ac-SDKP prevent fibrosis across multiple organs in animal studies, and Ac-SDKP can even reverse established scar tissue.
Reverses established fibrosisThe Tβ4 fragment Ac-SDKP not only prevents fibrosis but can reverse existing scar tissue in liver, lung, heart, and kidney animal models
What the researchers found
Thymosin beta-4 (Tβ4) prevents fibrosis and scarring in multiple animal models by reducing inflammation, decreasing macrophage infiltration, lowering levels of pro-fibrotic mediators (TGFβ, IL-10, CTGF), and preventing fibroblast conversion to myofibroblasts. The result is normally aligned collagen fibers rather than disordered scar tissue.
The N-terminal fragment of Tβ4, a tetrapeptide called Ac-SDKP (acetyl-serine-aspartate-lysine-proline), carries the majority of anti-fibrotic activity. Remarkably, Ac-SDKP can not only prevent fibrosis but also reverse established fibrosis in animal models of liver, lung, heart, and kidney fibrosis.
Why it matters
Fibrosis — the buildup of scar tissue in organs — is a component of many chronic diseases affecting the liver, lungs, heart, and kidneys, and currently has very limited treatment options. A peptide that can both prevent and reverse fibrosis across multiple organs would be a breakthrough therapeutic. Thymosin beta-4 and its fragment Ac-SDKP represent some of the most promising anti-fibrotic peptide candidates.
The numbers in context
Tβ4 effective in multiple organ fibrosis models · Ac-SDKP (4 amino acids) carries majority of anti-fibrotic activity · Reduces TGFβ, IL-10, CTGF · Prevents + reverses fibrosis
How the study worked
Narrative review synthesizing preclinical evidence from multiple animal models of fibrosis (liver, lung, heart, kidney) and wound healing. Covers the molecular mechanisms of Tβ4's anti-fibrotic action, including effects on macrophages, fibroblasts, and collagen organization.
Who was studied
Review of preclinical animal models of fibrosis (liver, lung, heart, kidney) and wound healing
What this study cannot tell us
Evidence is primarily from animal models; human clinical data on anti-fibrotic applications is limited. The review does not provide quantitative comparisons of efficacy across different organ systems. Optimal dosing, delivery methods, and potential combination strategies with existing drugs remain to be fully explored.
How to read the evidence
This is a narrative review of preclinical evidence from multiple animal models. The consistency of results across different organ systems strengthens the case, but human clinical data for anti-fibrotic applications remains limited.
When this study was published
Published in 2023, this review captures current understanding of Tβ4's anti-fibrotic mechanisms. Thymosin beta-4 research has been ongoing for decades, with clinical development continuing.
The bigger picture
Fibrosis contributes to an estimated 45% of deaths in the developed world, yet anti-fibrotic treatment options remain extremely limited. Thymosin beta-4 and Ac-SDKP stand out because they work across multiple organ systems through a shared anti-inflammatory mechanism. If these results translate to humans, peptide-based anti-fibrotic therapy could address a massive unmet medical need.
Questions still open
- Can Ac-SDKP reverse established fibrosis in human patients as effectively as in animal models?
- Would combining Tβ4 or Ac-SDKP with approved anti-fibrotic drugs like pirfenidone or nintedanib produce synergistic benefits?
- What is the optimal route and frequency of administration for anti-fibrotic peptide therapy in different organ systems?
Common questions
What is thymosin beta-4?
What makes Ac-SDKP special compared to the full thymosin beta-4 peptide?
Read the original research
Thymosin β4 and the anti-fibrotic switch.
International immunopharmacology, 115, 109628
Citation
Kleinman, Hynda K; Kulik, Veronika; Goldstein, Allan L. (2023). Thymosin β4 and the anti-fibrotic switch.. International immunopharmacology, 115, 109628. https://doi.org/10.1016/j.intimp.2022.109628